With over 23 years of dedication to the Taiwanese market, Sunmax Biotechnology Co., Ltd. continues to innovate in the field of collagen applications. On May 3rd, the company held the “Next-Generation Collagen Deusaderm ULTRA Product Launch” in Taipei, attracting over 100 industry professionals and international guests to explore the latest achievements in material research and trends in applications. This event also marked another milestone in Sunmax’s ongoing progress in collagen research, development, and manufacturing technology.
As Asia’s first GMP-certified medical device manufacturer to achieve mass production of medical-grade collagen, Sunmax Biotech upholds a philosophy of advancing both quality and innovation, while continuing to increase investment in the research and development of advanced injectable dermal materials.
The newly launched next-generation collagen injectable, Deusaderm ULTRA, incorporates the company’s proprietary TCT triple cross-linking technology, which enhances material structural stability and viscoelasticity. By improving both structural integrity and physical properties, the product offers greater flexibility in clinical applications.
This technology has been granted patents in several regions, including the United States, China, and Taiwan, and has successfully passed the full set of ISO 10993 biocompatibility tests. The product is manufactured in compliance with EU ISO 13485 and international QMS standards, demonstrating performance that meets rigorous quality management requirements.
At the product launch event, Sunmax invited several doctors with extensive clinical experience to share their observations and experiences using the next-generation collagen. The discussions focused on the physical properties, clinical handling, and application methods of Deusaderm ULTRA, providing professional medical insights. Sunmax Biotech emphasized that all product development strictly follows regulatory review procedures, and that its manufacturing processes and formulations are continuously refined based on clinical needs and scientific evidence.
Mr. Magnet LIN, Chief Learning Officer of Sunmax Biotech, stated, “We have long been committed to innovative research and development in collagen technology. Through more efficient manufacturing processes and internationally aligned quality management systems, we aim to bring Taiwan’s high-quality technology to the global market. At the same time, we will continue to respond to feedback from clinical users, helping healthcare providers offer safe and effective product options.”
The “Deusaderm ULTRA” product has received medical device approval from the Taiwan’s Ministry of Health and Welfare, passing regulatory review and demonstrating long-lasting performance.
Sunmax Biotech reminds the public that collagen injectable products are intended for professional medical use only and should be evaluated and administered by qualified medical institutions and healthcare professionals. Consumers are advised not to purchase or use them independently and should follow physicians’ professional recommendations for treatment or use.
Looking ahead, Sunmax Biotech will continue to deepen its collaborations with clinical and academic research institutions, focusing on the research and application of collagen injectable materials. The company will actively promote technological innovation and is committed to developing products with greater clinical application value to meet market demand.
At the same time, Sunmax Biotech is accelerating its expansion into overseas markets and refining its technology through ongoing clinical experience to advance Taiwan’s medical materials industry onto the global stage. This strategy aims not only to increase market share but also to promote Taiwan’s medical technology and products worldwide, further enhancing the brand’s international recognition.